Schistosomiasis is a neglected parasitosis caused by Schistosoma spp. Praziquantel is used for 17 the chemoprophylaxis and treatment of this disease. Although this monotherapy is effective, the risk 18 of resistance and its low efficiency against immature worms compromises its effectiveness. 19 Therefore, it is necessary to develop new schistosomicide drugs. However, the development of new 20 drugs is a long and expensive process. The repositioning of approved drugs has been proposed as a 21 quick, cheap, and effective alternative to solve this problem. This study employs chemogenomic 22 analysis with use of bioinformatics tools to search, identify, and analyze data on approved drugs with 23 the potential to inhibit Schistosoma mansoni energy metabolism enzymes. The TDR Targets 24 Database, Gene DB, Protein, DrugBank, Therapeutic Targets Database (TTD), Promiscuous, and 2 25
Introduction 32 necessary [9, 10] . This strategy focuses on energy metabolism enzymes, as they are considered 48 interesting targets for inhibitor development because they reduce energy production capacity, 49 consequently contributing to the death and elimination of the parasite [11] .
3 50 Conventional research and development strategies for novel drugs are considered high-cost 51 (estimated at millions of dollars), time-consuming (between 10-17 years), and risky. The serious 52 side-effects and diminished efficacy in humans that can occur during clinical trials are common 53 factors leading to a compound not being approved for commercialization [12, 13] . Moreover, 54 pharmaceutical industries are not interested in investing in the development and production of new 55 drugs for treating Neglected Tropical Diseases (NTDs), because they offer a low profit return [14] . 56 To overcome these difficulties, the repositioning of approved drugs is proposed, which offers 57 an excellent cost-benefit ratio by diminishing the time (between 3-12 years) and money spent 58 compared to the time and cost of developing new compounds. This strategy consists of identifying 59 new therapeutic indications for already approved drugs to treat other illnesses and/or those with 60 already discovered targets [10, 13, [15] [16] [17] [18] . In silico analysis, guided by databases that provide 61 information about potential off-target drug interactions, allows the prediction of side effects and the 62 identification of compounds that are candidates for repositioning [19] [20] [21] . Using this strategy, the 63 probability of success increases during in vitro and in vivo tests, the risk of failure is reduced, and the 64 experimentation on animals is rationalized [15, 22] . TTD contained 2,589 targets and around 31,614 drugs, of which 2,071 were approved and 7,291 were 115 in the clinical trial phase [28] .
116
In these two databases, the general strategy was based on the principle of target similarity, 117 where each S. mansoni energy metabolism target was compared with other targets that already have 118 approved drugs for treatment. All homologous drug targets with an expectation value (E-value) less 119 than 1  10 -5 obtained from the databases were input into a table as potential targets. On the initial DrugBank page, in the "Search" option, "Target Sequences" was selected. Then, 124 we inserted the protein sequence for consultation. The BLAST parameters offered by the database 125 were maintained and in the "drug types" filter, the option "approved" was marked. In the initial TTD page, the "Target Similarity" option was selected and the peptide sequence 129 was introduced into the "Input your protein sequence in FASTA format" field, and the "Search" 130 function was executed. All the results with an E-value less than 1  10 -5 were considered for analysis. From the results obtained regarding potential drug targets, we select those that interacted with 135 compounds approved for clinical use in human beings. The following parameters were introduced in 136 the table for targets with positive outcomes: "Name(s) of homologous target(s)" (Drug Bank and 137 TTD), "Target ID(s)" (DrugBank and TTD), "Pharmacological indication" (DrugBank), and "Drug 138 approval phase" (DrugBank and TTD) ( Table 1) . Promiscuous version 3.0 (http://bioinformatics.charite.de/promiscuous/) contains information 144 on 25,000 drugs, 1,100 different side effects, and 12,000 protein targets. Moreover, this database 145 makes information available on protein-protein and drug-protein interactions [29] .
146
Promiscuous offers different search strategies to the user: drug name, target by interest, and 147 metabolic pathway. In the present study, the search strategy chosen was to use the drug name. On the 148 initial page, the "Drugs" option was selected, and each drug name was inserted into the "Drug name" 149 field. Subsequently, the code of each drug was inserted into the PubChem field, found at 7 150 https://pubchem.ncbi.nlm.nih.go [30] , and the "Only with targets" option was selected. Information 151 on the interaction between the drug and protein target and the eventual side effects were separately 152 included in a table (Table 2) .
153
After obtaining results of interactions between drugs and protein targets and their side effects, In the TDR Targets Database, 59 genes were identified that encode S. mansoni energy 182 metabolism enzymes. All the products of these genes were considered as potential therapeutic targets 183 (Table 3) . The DrugBank and TTD databases returned 11 and one targets, respectively, with approved 189 drugs against them. The protein targets and their respective functions are presented in Table 1 . Involved in the glutamine metabolic process Of the ten targets, eight had high chemotherapeutic potential because of their very low E-210 values. Five targets that interact with seven high potential anti-schistosomiasis drugs were selected.
211
Detailed information on these compounds is presented in Table 2 . In this analysis, drugs identified as having therapeutic potential against schistosomiasis were 220 considered if they had a low cost, were approved for use in humans, and possessed few side effects.
221
Interactions of drugs identified with other targets were investigated using the Promiscuous database 222 to meet this last criterion. Each of the drugs was subjected to analysis, and 18 of them presented 223 interactions with different molecules. In this study, only the interaction networks of drugs with high 224 anti-schistosomiasis potential were detailed (Table 2) . To evaluate in vivo anti-schistosomiasis activity of thiabendazole and albendazole in mice 307 infected with S. mansoni, 100 mg/kg/day and 500 mg/kg/day doses were used, respectively. In this 308 assessment, it was found that albendazole treatment showed no effect on the number of dead adult 309 specimens and/or the elimination of eggs from this parasite. In contrast, treatment using thiabendazole 310 significantly increased the mortality of adult worms [32] . The study's main purpose was to identify new anti-schistosomiasis drugs using an in silico 315 repositioning strategy with drugs approved for treating other diseases. The following is a discussion 16 316 of each of the drugs identified in the present study and their potential effects on S. mansoni energy 317 metabolism.
318
Fomepizole is indicated for treating methanol poisoning or used when the ingestion of 319 ethylene glycol is suspected [33] . This drug acts as an inhibitor of alcohol dehydrogenase 1B, present 320 in human metabolism [34] . In this target, fomepizole inhibits the oxidation of ethanol to acetaldehyde 321 (DrugBank data). In the present study, fomepizole was identified as having the capacity to inhibit 322 (Smp_044440) alcohol dehydrogenase (Table 2) , as both cited targets present similar functions.
323
Results obtained from the Promiscuous database reveal that fomepizole also inhibits catalase was identified as presenting potential to inhibit mitochondrial ATP synthase delta chain 335 (Smp_082120) ( hydrolysis catalyst that is also involved in calcium transport ( Fig S4) This study presents an in silico repositioning strategy to identify new drugs for treating 373 intestinal schistosomiasis based on the principle of target similarity to identify drugs approved for 374 clinical use in humans. Twenty drugs were identified, eight of which have high schistosomicide 375 potential. The action of the drugs was compared among the targets using databases that presented 376 interaction analysis of the drug with other targets. Using this methodology, it was possible to confirm 377 the drug-protein target interaction, as well as the interaction with other targets that may or may not 378 have roles in energy metabolism. Furthermore, information was obtained on possible side effects of 379 the identified drugs. However, it is important to emphasize that there are no guarantees that the 380 identified compounds will act on S. mansoni energy metabolism targets. 
